<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37324463</PMID><DateRevised><Year>2023</Year><Month>06</Month><Day>19</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Prophylactic rivaroxaban in the early post-discharge period reduces the rates of hospitalization for atrial fibrillation and incidence of sudden cardiac death during long-term follow-up in hospitalized COVID-19 survivors.</ArticleTitle><Pagination><StartPage>1093396</StartPage><MedlinePgn>1093396</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1093396</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2023.1093396</ELocationID><Abstract><AbstractText><b>Introduction:</b> While acute Coronavirus disease 2019 (COVID-19) affects the cardiovascular (CV) system according to recent data, an increased CV risk has been reported also during long-term follow-up (FU). In addition to other CV pathologies in COVID-19 survivors, an enhanced risk for arrhythmic events and sudden cardiac death (SCD) has been observed. While recommendations on post-discharge thromboprophylaxis are conflicting in this population, prophylactic short-term rivaroxaban therapy after hospital discharge showed promising results. However, the impact of this regimen on the incidence of cardiac arrhythmias has not been evaluated to date. <b>Methods:</b> To investigate the efficacy of this therapy, we conducted a single center, retrospective analysis of 1804 consecutive, hospitalized COVID-19 survivors between April and December 2020. Patients received either a 30-day post-discharge thromboprophylaxis treatment regimen using rivaroxaban 10&#xa0;mg every day (QD) (Rivaroxaban group (Riva); <i>n</i> = 996) or no thromboprophylaxis (Control group (Ctrl); <i>n</i> = 808). Hospitalization for new atrial fibrillation (AF), new higher-degree Atrioventricular-block (AVB) as well as incidence of SCD were investigated in 12-month FU [FU: 347 (310/449) days]. <b>Results:</b> No differences in baseline characteristics (Ctrl vs Riva: age: 59.0 (48.9/66.8) vs 57 (46.5/64.9) years, <i>p</i> = <i>n</i>.s.; male: 41.5% vs 43.7%, <i>p</i> = <i>n</i>.s.) and in the history of relevant CV-disease were observed between the two groups. While hospitalizations for AVB were not reported in either group, relevant rates of hospitalizations for new AF (0.99%, <i>n</i> = 8/808) as well as a high rate of SCD events (2.35%, <i>n</i> = 19/808) were seen in the Ctrl. These cardiac events were attenuated by early post-discharge prophylactic rivaroxaban therapy (AF: <i>n</i> = 2/996, 0.20%, <i>p</i> = 0.026 and SCD: n = 3/996, 0.30%, <i>p</i> &lt; 0.001) which was also observed after applying a logistic regression model for propensity score matching (AF: <i>&#x3c7;</i> <sup>2</sup>-statistics = 6.45, <i>p</i> = 0.013 and SCD: <i>&#x3c7;</i> <sup>2</sup>-statistics = 9.33, <i>p</i> = 0.002). Of note, no major bleeding complications were observed in either group. <b>Conclusion:</b> Atrial arrhythmic and SCD events are present during the first 12&#xa0;months after hospitalization for COVID-19. Extended prophylactic Rivaroxaban therapy after hospital discharge could reduce new onset of AF and SCD in hospitalized COVID-19 survivors.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 Fiedler, Motloch, Dieplinger, Jirak, Davtyan, Gareeva, Badykova, Badykov, Lakman, Agapitov, Sadikova, Pavlov, F&#xf6;ttinger, Mirna, Kopp, Hoppe, Pistulli, Cai, Yang and Zagidullin.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fiedler</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University Department of Internal Medicine II, Cardiology and Internal Intensive Care Medicine, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Nephrology and Intensive Care Medicine, Hospital Wiener Neustadt, Wiener Neustadt, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Motloch</LastName><ForeName>Lukas J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>University Department of Internal Medicine II, Cardiology and Internal Intensive Care Medicine, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dieplinger</LastName><ForeName>Anna-Maria</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Nursing Science Program, Institute for Nursing Science and Practice, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Faculty, Johannes Kepler University Linz, Linz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jirak</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>University Department of Internal Medicine II, Cardiology and Internal Intensive Care Medicine, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davtyan</LastName><ForeName>Paruir</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Diseases, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gareeva</LastName><ForeName>Diana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Internal Diseases, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badykova</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Internal Diseases, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Badykov</LastName><ForeName>Marat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Diseases, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lakman</LastName><ForeName>Irina</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Internal Diseases, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scientific Laboratory for the Socio-Economic Region Problems Investigation, Ufa University of Science and Technology, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agapitov</LastName><ForeName>Aleksandr</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Scientific Laboratory for the Socio-Economic Region Problems Investigation, Ufa University of Science and Technology, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sadikova</LastName><ForeName>Liana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Scientific Laboratory for the Socio-Economic Region Problems Investigation, Ufa University of Science and Technology, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pavlov</LastName><ForeName>Valentin</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Urology, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>F&#xf6;ttinger</LastName><ForeName>Fabian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>University Department of Internal Medicine II, Cardiology and Internal Intensive Care Medicine, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirna</LastName><ForeName>Moritz</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University Department of Internal Medicine II, Cardiology and Internal Intensive Care Medicine, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kopp</LastName><ForeName>Kristen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University Department of Internal Medicine II, Cardiology and Internal Intensive Care Medicine, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hoppe</LastName><ForeName>Uta C</ForeName><Initials>UC</Initials><AffiliationInfo><Affiliation>University Department of Internal Medicine II, Cardiology and Internal Intensive Care Medicine, Paracelsus Medical University, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pistulli</LastName><ForeName>Rudin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Cardiology I, Coronary and Peripheral Vascular Disease, Heart Failure, University Hospital Muenster, Muenster, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Benzhi</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmacology (The Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Baofeng</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Pharmacology (The Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zagidullin</LastName><ForeName>Naufal</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Diseases, Bashkir State Medical University, Ufa, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Ufa University of Science and Technology, Ufa, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">NOAC</Keyword><Keyword MajorTopicYN="N">SCD</Keyword><Keyword MajorTopicYN="N">atrial fibrillation</Keyword><Keyword MajorTopicYN="N">long COVID-19</Keyword><Keyword MajorTopicYN="N">post-acute COVID-19 sequelae</Keyword><Keyword MajorTopicYN="N">rivaroxaban</Keyword></KeywordList><CoiStatement>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>16</Day><Hour>4</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37324463</ArticleId><ArticleId IdType="pmc">PMC10266094</ArticleId><ArticleId IdType="doi">10.3389/fphar.2023.1093396</ArticleId><ArticleId IdType="pii">1093396</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aidouni G. el, Bouchlarhem A., Bkiyar H., Ismaili N., el Ouafi N., Housni B. (2023). The efficacy and safety of prolonged oral anticoagulation for the prevention of thromboembolic events in patients recovered from COVID-19 1 Year after hospital discharge: The SARCOV-19 prospective registry. Clin. Appl. Thromb. Hemost. 29, 1. 10.1177/10760296231151710</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/10760296231151710</ArticleId><ArticleId IdType="pmc">PMC9900156</ArticleId><ArticleId IdType="pubmed">36721349</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Horani R. A. (2020). Potential therapeutic roles for direct factor Xa inhibitors in coronavirus infections. Am. J. Cardiovasc Drugs 20, 525&#x2013;533. 10.1007/S40256-020-00438-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S40256-020-00438-6</ArticleId><ArticleId IdType="pmc">PMC7486161</ArticleId><ArticleId IdType="pubmed">32918208</ArticleId></ArticleIdList></Reference><Reference><Citation>Ambrus D. B., Benjamin E. J., Bajwa E. K., Hibbert K. A., Walkey A. J. (2015). Risk factors and outcomes associated with new-onset atrial fibrillation during acute respiratory distress syndrome. J. Crit. Care 30, 994&#x2013;997. 10.1016/J.JCRC.2015.06.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JCRC.2015.06.003</ArticleId><ArticleId IdType="pmc">PMC4681683</ArticleId><ArticleId IdType="pubmed">26138630</ArticleId></ArticleIdList></Reference><Reference><Citation>Babapoor-Farrokhran S., Rasekhi R. T., Gill D., Babapoor S., Amanullah A. (2020). Arrhythmia in COVID-19. SN Compr. Clin. Med. 2, 1430&#x2013;1435. 10.1007/S42399-020-00454-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S42399-020-00454-2</ArticleId><ArticleId IdType="pmc">PMC7426193</ArticleId><ArticleId IdType="pubmed">32838188</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman J. P., Abrams M. P., Kushnir A., Rubin G. A., Ehlert F., Biviano A., et al. (2020). Cardiac electrophysiology consultative experience at the epicenter of the COVID-19 pandemic in the United States. Indian Pacing Electrophysiol. J. 20, 250. 10.1016/J.IPEJ.2020.08.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.IPEJ.2020.08.006</ArticleId><ArticleId IdType="pmc">PMC7450949</ArticleId><ArticleId IdType="pubmed">32861812</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatla A., Mayer M. M., Adusumalli S., Hyman M. C., Oh E., Tierney A., et al. (2020). COVID-19 and cardiac arrhythmias. Heart rhythm. 17, 1439&#x2013;1444. 10.1016/J.HRTHM.2020.06.016</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.HRTHM.2020.06.016</ArticleId><ArticleId IdType="pmc">PMC7307518</ArticleId><ArticleId IdType="pubmed">32585191</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B., Madhavan M. v., Jimenez D., Chuich T., Dreyfus I., Driggin E., et al. (2020). COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J. Am. Coll. Cardiol. 75, 2950&#x2013;2973. 10.1016/J.JACC.2020.04.031</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JACC.2020.04.031</ArticleId><ArticleId IdType="pmc">PMC7164881</ArticleId><ArticleId IdType="pubmed">32311448</ArticleId></ArticleIdList></Reference><Reference><Citation>Bukowska A., Zacharias I., Weinert S., Skopp K., Hartmann C., Huth C., et al. (2013). Coagulation factor Xa induces an inflammatory signalling by activation of protease-activated receptors in human atrial tissue. Eur. J. Pharmacol. 718, 114&#x2013;123. 10.1016/J.EJPHAR.2013.09.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.EJPHAR.2013.09.006</ArticleId><ArticleId IdType="pubmed">24041930</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho-Schneider C., Laurent E., Lemaignen A., Beaufils E., Bourbao-Tournois C., Laribi S., et al. (2021). Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin. Microbiol. Infect. 27, 258&#x2013;263. 10.1016/J.CMI.2020.09.052</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CMI.2020.09.052</ArticleId><ArticleId IdType="pmc">PMC7534895</ArticleId><ArticleId IdType="pubmed">33031948</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C. J., Chen Y. C., Lin Y. K., Huang J. H., Chen S. A., Chen Y. J. (2013). Rivaroxaban modulates electrical and mechanical characteristics of left atrium. J. Biomed. Sci. 20, 1. 10.1186/1423-0127-20-17</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1423-0127-20-17</ArticleId><ArticleId IdType="pmc">PMC3608950</ArticleId><ArticleId IdType="pubmed">23497194</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang C. J., Cheng C. C., Chen Y. C., Higa S., Huang J. H., Chen S. A., et al. (2018). Factor Xa inhibitors differently modulate electrical activities in pulmonary veins and the sinoatrial node. Eur. J. Pharmacol. 833, 462&#x2013;471. 10.1016/J.EJPHAR.2018.07.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.EJPHAR.2018.07.003</ArticleId><ArticleId IdType="pubmed">30017860</ArticleId></ArticleIdList></Reference><Reference><Citation>Colon C. M., Barrios J. G., Chiles J. W., McElwee S. K., Russell D. W., Maddox W. R., et al. (2020). Atrial arrhythmias in COVID-19 patients. JACC Clin. Electrophysiol. 6, 1189&#x2013;1190. 10.1016/J.JACEP.2020.05.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JACEP.2020.05.015</ArticleId><ArticleId IdType="pmc">PMC7253953</ArticleId><ArticleId IdType="pubmed">32972558</ArticleId></ArticleIdList></Reference><Reference><Citation>Connors J. M., Levy J. H. (2020). COVID-19 and its implications for thrombosis and anticoagulation. Blood 135, 2033&#x2013;2040. 10.1182/BLOOD.2020006000</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/BLOOD.2020006000</ArticleId><ArticleId IdType="pmc">PMC7273827</ArticleId><ArticleId IdType="pubmed">32339221</ArticleId></ArticleIdList></Reference><Reference><Citation>Delabranche X., Helms J., Meziani F. (2017). Immunohaemostasis: A new view on haemostasis during sepsis. Ann. Intensive Care 7, 1. 10.1186/S13613-017-0339-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/S13613-017-0339-5</ArticleId><ArticleId IdType="pmc">PMC5712298</ArticleId><ArticleId IdType="pubmed">29197958</ArticleId></ArticleIdList></Reference><Reference><Citation>Demelo-Rodr&#xed;guez P., Ordieres-Ortega L., Ji Z., del Toro-Cervera J., de Miguel-D&#xed;ez J., &#xc1;lvarez-Sala-Walther L. A., et al. (2021). Long-term follow-up of patients with venous thromboembolism and COVID-19: Analysis of risk factors for death and major bleeding. Eur. J. Haematol. 106, 716&#x2013;723. 10.1111/EJH.13603</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/EJH.13603</ArticleId><ArticleId IdType="pmc">PMC8013455</ArticleId><ArticleId IdType="pubmed">33608914</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelmann B., Massberg S. (2013). Thrombosis as an intravascular effector of innate immunity. Nat. Rev. Immunol. 13, 34&#x2013;45. 10.1038/NRI3345</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/NRI3345</ArticleId><ArticleId IdType="pubmed">23222502</ArticleId></ArticleIdList></Reference><Reference><Citation>Esmon C. T. (2012). Protein C anticoagulant system--anti-inflammatory effects. Semin. Immunopathol. 34, 127&#x2013;132. 10.1007/S00281-011-0284-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00281-011-0284-6</ArticleId><ArticleId IdType="pmc">PMC3233668</ArticleId><ArticleId IdType="pubmed">21822632</ArticleId></ArticleIdList></Reference><Reference><Citation>Feistritzer C., Lenta R., Riewald M. (2005). Protease-activated receptors-1 and -2 can mediate endothelial barrier protection: Role in factor Xa signaling. J. Thromb. Haemost. 3, 2798&#x2013;2805. 10.1111/J.1538-7836.2005.01610.X</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/J.1538-7836.2005.01610.X</ArticleId><ArticleId IdType="pubmed">16359518</ArticleId></ArticleIdList></Reference><Reference><Citation>Fender A. C., Wakili R., Dobrev D. (2019). Straight to the Heart: Pleiotropic antiarrhythmic actions of oral anticoagulants. Pharmacol. Res. 145, 104257. 10.1016/J.PHRS.2019.104257</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.PHRS.2019.104257</ArticleId><ArticleId IdType="pmc">PMC6987959</ArticleId><ArticleId IdType="pubmed">31054953</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannis D., Allen S. L., Tsang J., Flint S., Pinhasov T., Williams S., et al. (2021). Postdischarge thromboembolic outcomes and mortality of hospitalized patients with COVID-19: The CORE-19 registry. Blood 137, 2838&#x2013;2847. 10.1182/BLOOD.2020010529</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/BLOOD.2020010529</ArticleId><ArticleId IdType="pmc">PMC8032474</ArticleId><ArticleId IdType="pubmed">33824972</ArticleId></ArticleIdList></Reference><Reference><Citation>Glikson M., Nielsen J. C., Kronborg M. B., Michowitz Y., Auricchio A., Barbash I. M., et al. (2021). 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur. Heart J. 42, 3427&#x2013;3520. 10.1093/EURHEARTJ/EHAB364</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/EURHEARTJ/EHAB364</ArticleId><ArticleId IdType="pubmed">34586378</ArticleId></ArticleIdList></Reference><Reference><Citation>Go&#xeb;rtz Y. M. J., van Herck M., Delbressine J. M., Vaes A. W., Meys R., Machado F. V. C., et al. (2020). Persistent symptoms 3 months after a SARS-CoV-2 infection: The post-COVID-19 syndrome? ERJ Open Res. 6, 00542. 10.1183/23120541.00542-2020</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00542-2020</ArticleId><ArticleId IdType="pmc">PMC7491255</ArticleId><ArticleId IdType="pubmed">33257910</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T., Fan Y., Chen M., Wu X., Zhang L., He T., et al. (2020). Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 5, 811&#x2013;818. 10.1001/JAMACARDIO.2020.1017</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMACARDIO.2020.1017</ArticleId><ArticleId IdType="pmc">PMC7101506</ArticleId><ArticleId IdType="pubmed">32219356</ArticleId></ArticleIdList></Reference><Reference><Citation>Hadi H. A. R., Alsheikh-Ali A. A., Mahmeed W. A. L., Suwaidi J. M. A. (2010). Inflammatory cytokines and atrial fibrillation: Current and prospective views. J. Inflamm. Res. 3, 75&#x2013;97. 10.2147/JIR.S10095</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S10095</ArticleId><ArticleId IdType="pmc">PMC3218735</ArticleId><ArticleId IdType="pubmed">22096359</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y. F., Chen Y. J., Lin Y. J., Chen S. A. (2015). Inflammation and the pathogenesis of atrial fibrillation. Nat. Rev. Cardiol. 12, 230&#x2013;243. 10.1038/nrcardio.2015.2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2015.2</ArticleId><ArticleId IdType="pubmed">25622848</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., et al. (2021). 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet 397, 220&#x2013;232. 10.1016/S0140-6736(20)32656-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T., Levy J. H. (2019). Derangement of the endothelial glycocalyx in sepsis. J. Thromb. Haemost. 17, 283&#x2013;294. 10.1111/JTH.14371</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/JTH.14371</ArticleId><ArticleId IdType="pubmed">30582882</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T., Levy J. H. (2018). Inflammation and thrombosis: Roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis. J. Thromb. Haemost. 16, 231&#x2013;241. 10.1111/JTH.13911</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/JTH.13911</ArticleId><ArticleId IdType="pubmed">29193703</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson S. P., Darbousset R., Schoenwaelder S. M. (2019). Thromboinflammation: Challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood 133, 906&#x2013;918. 10.1182/BLOOD-2018-11-882993</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/BLOOD-2018-11-882993</ArticleId><ArticleId IdType="pubmed">30642917</ArticleId></ArticleIdList></Reference><Reference><Citation>Jirak P., Larbig R., Shomanova Z., Fr&#xf6;b E. J., Dankl D., Torgersen C., et al. (2021a). Myocardial injury in severe COVID-19 is similar to pneumonias of other origin: Results from a multicentre study. Esc. Heart Fail 8, 1. 10.1002/ehf2.13136</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.13136</ArticleId><ArticleId IdType="pmc">PMC7835505</ArticleId><ArticleId IdType="pubmed">33350605</ArticleId></ArticleIdList></Reference><Reference><Citation>Jirak P., Shomanova Z., Larbig R., Dankl D., Frank N., Seelmaier C., et al. (2021b). Higher incidence of stroke in severe COVID-19 is not associated with a higher burden of arrhythmias: Comparison with other types of severe pneumonia. Front. Cardiovasc Med. 8, 763827. 10.3389/fcvm.2021.763827</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2021.763827</ArticleId><ArticleId IdType="pmc">PMC8652060</ArticleId><ArticleId IdType="pubmed">34901224</ArticleId></ArticleIdList></Reference><Reference><Citation>Jirak P., van Almsick V., Dimitroulis D., Mirna M., Seelmaier C., Shomanova Z., et al. (2022). Dexamethasone improves cardiovascular outcomes in critically ill COVID-19, a real World scenario multicenter analysis. Front. Med. (Lausanne) 9, 808221. 10.3389/fmed.2022.808221</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.808221</ArticleId><ArticleId IdType="pmc">PMC8847392</ArticleId><ArticleId IdType="pubmed">35186995</ArticleId></ArticleIdList></Reference><Reference><Citation>Jobi K., Rauch B. H., Dangwal S., Freidel K., Doller A., Eberhardt W., et al. (2011). Redox regulation of human protease-activated receptor-2 by activated factor X. Free Radic. Biol. Med. 51, 1758&#x2013;1764. 10.1016/J.FREERADBIOMED.2011.08.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.FREERADBIOMED.2011.08.003</ArticleId><ArticleId IdType="pubmed">21871560</ArticleId></ArticleIdList></Reference><Reference><Citation>Jumeau C., Rupin A., Chieng-Yane P., Mougenot N., Zahr N., David-Dufilho M., et al. (2016). Direct thrombin inhibitors prevent left atrial remodeling associated with heart failure in rats. JACC Basic Transl. Sci. 1, 328. 10.1016/J.JACBTS.2016.05.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JACBTS.2016.05.002</ArticleId><ArticleId IdType="pmc">PMC5012373</ArticleId><ArticleId IdType="pubmed">27642643</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaatz S., Ahmad D., Spyropoulos A. C., Schulman S. (2015). Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: Communication from the SSC of the ISTH. J. Thromb. Haemost. 13, 2119&#x2013;2126. 10.1111/JTH.13140</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/JTH.13140</ArticleId><ArticleId IdType="pubmed">26764429</ArticleId></ArticleIdList></Reference><Reference><Citation>Katoh H., Nozue T., Michishita I. (2017). Anti-inflammatory effect of factor-Xa inhibitors in Japanese patients with atrial fibrillation. Heart Vessels 32, 1130&#x2013;1136. 10.1007/S00380-017-0962-Y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S00380-017-0962-Y</ArticleId><ArticleId IdType="pubmed">28283738</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenan Aksu, Aayhan Donmez, Goakha Keser. (2012). Inflammation-induced thrombosis: Mechanisms, disease associations and management. Curr. Pharm. Des. 18, 1478&#x2013;1493. 10.2174/138161212799504731</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138161212799504731</ArticleId><ArticleId IdType="pubmed">22364132</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein Klouwenberg P. M. C., Frencken J. F., Kuipers S., Ong D. S. Y., Peelen L. M., van Vught L. A., et al. (2017). Incidence, predictors, and outcomes of new-onset atrial fibrillation in critically ill patients with sepsis. A cohort study. Am. J. Respir. Crit. Care Med. 195, 205&#x2013;211. 10.1164/RCCM.201603-0618OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/RCCM.201603-0618OC</ArticleId><ArticleId IdType="pubmed">27467907</ArticleId></ArticleIdList></Reference><Reference><Citation>Kochav S. M., Coromilas E., Nalbandian A., Ranard L. S., Gupta A., Chung M. K., et al. (2020). Cardiac arrhythmias in COVID-19 infection. Circ. Arrhythm. Electrophysiol. 13, 579&#x2013;585. 10.1161/CIRCEP.120.008719</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCEP.120.008719</ArticleId><ArticleId IdType="pmc">PMC7299099</ArticleId><ArticleId IdType="pubmed">32434385</ArticleId></ArticleIdList></Reference><Reference><Citation>Landfors F., Vikstr&#xf6;m S., Wennberg P., Jansson J. H., Andersson J., Chorell E. (2022). Leukotriene A4 hydrolase and hepatocyte growth factor are risk factors of sudden cardiac death due to first-ever myocardial infarction. Int. J. Mol. Sci. 23, 10251. 10.3390/IJMS231810251/S1</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/IJMS231810251/S1</ArticleId><ArticleId IdType="pmc">PMC9499415</ArticleId><ArticleId IdType="pubmed">36142157</ArticleId></ArticleIdList></Reference><Reference><Citation>Lau S. T., Yu W. C., Mok N. S., Tsui P. T., Tong W. L., Cheng S. W. C. (2005). Tachycardia amongst subjects recovering from severe acute respiratory syndrome (SARS). Int. J. Cardiol. 100, 167&#x2013;169. 10.1016/J.IJCARD.2004.06.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.IJCARD.2004.06.022</ArticleId><ArticleId IdType="pmc">PMC7132412</ArticleId><ArticleId IdType="pubmed">15820302</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J., Solus J., Chen Q., Rho Y. H., Milne G., Stein C. M., et al. (2010). Role of inflammation and oxidative stress in atrial fibrillation. Heart rhythm. 7, 438&#x2013;444. 10.1016/J.HRTHM.2009.12.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.HRTHM.2009.12.009</ArticleId><ArticleId IdType="pmc">PMC2843774</ArticleId><ArticleId IdType="pubmed">20153266</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R., Zhao X., Li J., Niu P., Yang B., Wu H., et al. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 395, 1. 10.1016/S0140-6736(20)30251-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30251-8</ArticleId><ArticleId IdType="pmc">PMC7159086</ArticleId><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins G. L., Duarte R. C. F., Vieira &#xc9;. L. M., Rocha N. P., Figueiredo E. L., Silveira F. R., et al. (2020). Comparison of inflammatory mediators in patients with atrial fibrillation using warfarin or rivaroxaban. Front. Cardiovasc Med. 7, 1. 10.3389/FCVM.2020.00114/FULL</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FCVM.2020.00114/FULL</ArticleId><ArticleId IdType="pmc">PMC7393940</ArticleId><ArticleId IdType="pubmed">32793635</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelen M., Manoharan L., Elkheir N., Cheng V., Dagens A., Hastie C., et al. (2021). Characterising long COVID: A living systematic review. BMJ Glob. Health 6, 1. 10.1136/BMJGH-2021-005427</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/BMJGH-2021-005427</ArticleId><ArticleId IdType="pmc">PMC8478580</ArticleId><ArticleId IdType="pubmed">34580069</ArticleId></ArticleIdList></Reference><Reference><Citation>Mountantonakis S. E., Saleh M., Fishbein J., Gandomi A., Lesser M., Chelico J., et al. (2021). Atrial fibrillation is an independent predictor for in-hospital mortality in patients admitted with SARS-CoV-2 infection. Heart rhythm. 18, 501&#x2013;507. 10.1016/J.HRTHM.2021.01.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.HRTHM.2021.01.018</ArticleId><ArticleId IdType="pmc">PMC7825902</ArticleId><ArticleId IdType="pubmed">33493650</ArticleId></ArticleIdList></Reference><Reference><Citation>Musikantow D. R., Turagam M. K., Sartori S., Chu E., Kawamura I., Shivamurthy P., et al. (2021). Atrial fibrillation in patients hospitalized with COVID-19: Incidence, predictors, outcomes, and comparison to influenza. JACC Clin. Electrophysiol. 7, 1120&#x2013;1130. 10.1016/J.JACEP.2021.02.009</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JACEP.2021.02.009</ArticleId><ArticleId IdType="pmc">PMC7904279</ArticleId><ArticleId IdType="pubmed">33895107</ArticleId></ArticleIdList></Reference><Reference><Citation>
Ortel T. L. (2023). COVID-19 thrombosis prevention trials: Post-hospital thromboprophylaxis - Full Text view - ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/show/NCT04650087 (Accessed March 5, 2023).</Citation></Reference><Reference><Citation>Paar V., Wernly B., Zhou Z., Motloch L. J., Hoppe U. C., Egle A., et al. (2021). Anti-coagulation for COVID-19 treatment: Both anti-thrombotic and anti-inflammatory? J. Thromb. Thrombolysis 51, 226&#x2013;231. 10.1007/S11239-020-02212-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/S11239-020-02212-6</ArticleId><ArticleId IdType="pmc">PMC7338133</ArticleId><ArticleId IdType="pubmed">32632558</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramacciotti E., Barile Agati L., Calderaro D., Aguiar V. C. R., Spyropoulos A. C., de Oliveira C. C. C., et al. (2022). Rivaroxaban versus no anticoagulation for post-discharge thromboprophylaxis after hospitalisation for COVID-19 (MICHELLE): An open-label, multicentre, randomised, controlled trial. Lancet 399, 50&#x2013;59. 10.1016/S0140-6736(21)02392-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02392-8</ArticleId><ArticleId IdType="pmc">PMC8673881</ArticleId><ArticleId IdType="pubmed">34921756</ArticleId></ArticleIdList></Reference><Reference><Citation>
Russian Ministry of Healthcare (2020). Version 8 of the temporal recommendations for the prevention, diagnosis and treatment of the novel coronavirus infection COVID-19. Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/051/777/original/030902020_COVID-19_v8.pdf (Accessed March 6, 2023).1.</Citation></Reference><Reference><Citation>Seeble J., Waterboer T., Hippchen T., Simon J., Kirchner M., Lim A., et al. (2022). Persistent symptoms in adult patients 1 Year after coronavirus disease 2019 (COVID-19): A prospective cohort study. Clin. Infect. Dis. 74, 1191&#x2013;1198. 10.1093/CID/CIAB611</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/CID/CIAB611</ArticleId><ArticleId IdType="pmc">PMC8394862</ArticleId><ArticleId IdType="pubmed">34223884</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinberg S. F. (2005). The cardiovascular actions of protease-activated receptors. Mol. Pharmacol. 67, 2&#x2013;11. 10.1124/MOL.104.003103</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/MOL.104.003103</ArticleId><ArticleId IdType="pubmed">15371558</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun J., Xiao J., Sun R., Tang X., Liang C., Lin H., et al. (2020). Prolonged persistence of SARS-CoV-2 RNA in body fluids. Emerg. Infect. Dis. 26, 1834&#x2013;1838. 10.3201/EID2608.201097</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/EID2608.201097</ArticleId><ArticleId IdType="pmc">PMC7392422</ArticleId><ArticleId IdType="pubmed">32383638</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry C. M., He Y., Cheung A. K. (2016). Rivaroxaban improves patency and decreases inflammation in a mouse model of catheter thrombosis. Thromb. Res. 144, 106&#x2013;112. 10.1016/J.THROMRES.2016.06.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.THROMRES.2016.06.008</ArticleId><ArticleId IdType="pmc">PMC4980169</ArticleId><ArticleId IdType="pubmed">27318247</ArticleId></ArticleIdList></Reference><Reference><Citation>Toloui A., Moshrefiaraghi D., Neishaboori A. M., Yousefifard M., Aghajani M. H. (2021). Cardiac complications and pertaining mortality rate in COVID-19 patients; a systematic review and meta-analysis. Arch. Acad. Emerg. Med. 9, 1&#x2013;7. 10.22037/AAEM.V9I1.1071</Citation><ArticleIdList><ArticleId IdType="doi">10.22037/AAEM.V9I1.1071</ArticleId><ArticleId IdType="pmc">PMC8035700</ArticleId><ArticleId IdType="pubmed">33870205</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Yu C., Jing H., Wu X., Novakovic V. A., Xie R., et al. (2022). Long COVID: The nature of thrombotic sequelae determines the necessity of early anticoagulation. Front. Cell Infect. Microbiol. 12. 10.3389/FCIMB.2022.861703</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/FCIMB.2022.861703</ArticleId><ArticleId IdType="pmc">PMC9016198</ArticleId><ArticleId IdType="pubmed">35449732</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., et al. (2020). Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in wuhan, China. JAMA 323, 1061&#x2013;1069. 10.1001/JAMA.2020.1585</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/JAMA.2020.1585</ArticleId><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiteley W., Wood A. (2022). Risk of arterial and venous thromboses after COVID-19. Lancet Infect. Dis. 22, 1093&#x2013;1094. 10.1016/S1473-3099(22)00314-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00314-0</ArticleId><ArticleId IdType="pmc">PMC9106313</ArticleId><ArticleId IdType="pubmed">35576962</ArticleId></ArticleIdList></Reference><Reference><Citation>
Who (2020). Clinical management of COVID-19: Interim guidance. World health organization. Available at: https://apps.who.int/iris/handle/10665/332196 (Accessed February 12, 2023).</Citation></Reference><Reference><Citation>Wollborn J., Karamnov S., Fields K. G., Yeh T., Muehlschlegel J. D. (2022). COVID-19 increases the risk for the onset of atrial fibrillation in hospitalized patients. Sci. Rep. 12, 6. 10.1038/S41598-022-16113-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/S41598-022-16113-6</ArticleId><ArticleId IdType="pmc">PMC9281233</ArticleId><ArticleId IdType="pubmed">35835807</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y., Xu E., Bowe B., Al-Aly Z. (2022). Long-term cardiovascular outcomes of COVID-19. Nat. Med. 28, 3. 10.1038/s41591-022-01689-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01689-3</ArticleId><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Q., Xu M., Li J., Liu Y., Zhang J., Xu Y., et al. (2021). Clinical sequelae of COVID-19 survivors in wuhan, China: A single-centre longitudinal study. Clin. Microbiol. Infect. 27, 89&#x2013;95. 10.1016/J.CMI.2020.09.023</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.CMI.2020.09.023</ArticleId><ArticleId IdType="pmc">PMC7510771</ArticleId><ArticleId IdType="pubmed">32979574</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C.-M., Wong R. S.-M., Wu E. B., Kong S.-L., Wong J., Yip G. W.-K., et al. (2006). Cardiovascular complications of severe acute respiratory syndrome. Postgrad. Med. J. 82, 140&#x2013;144. 10.1136/pgmj.2005.037515</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/pgmj.2005.037515</ArticleId><ArticleId IdType="pmc">PMC2596695</ArticleId><ArticleId IdType="pubmed">16461478</ArticleId></ArticleIdList></Reference><Reference><Citation>Zagidullin N. S., Motloch L. J., Musin T. I., Bagmanova Z. A., Lakman I. A., Tyurin A. V., et al. (2021). J-Waves in acute COVID-19: A novel disease characteristic and predictor of mortality? PLoS One 16. 0257982. 10.1371/journal.pone.0257982</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0257982</ArticleId><ArticleId IdType="pmc">PMC8516278</ArticleId><ArticleId IdType="pubmed">34648510</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeppenfeld K., Tfelt-Hansen J., de Riva M., Winkel B. G., Behr E. R., Blom N. A., et al. (2022). 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac deathDeveloped by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC) Endorsed by the Association for European Paediatric and Congenital Cardiology (AEPC). Eur. Heart J. 43 (40), 3997&#x2013;4126. 10.1093/EURHEARTJ/EHAC262</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/EURHEARTJ/EHAC262</ArticleId><ArticleId IdType="pubmed">36017572</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Lu X., Wan F., Gao L., Lin N., He J., et al. (2022). Disruption of circadian rhythms by shift work exacerbates reperfusion injury in myocardial infarction. J. Am. Coll. Cardiol. 79, 2097&#x2013;2115. 10.1016/J.JACC.2022.03.370</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/J.JACC.2022.03.370</ArticleId><ArticleId IdType="pmc">PMC8972444</ArticleId><ArticleId IdType="pubmed">35618347</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou M., Wong C. K., Lau Y. M., Lee J. C. Y., Tam F. C. C., Lau Y. M., et al. (2021). Cardiovascular sequalae in uncomplicated COVID-19 survivors. PLoS One 16, 1. 10.1371/JOURNAL.PONE.0246732</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/JOURNAL.PONE.0246732</ArticleId><ArticleId IdType="pmc">PMC7877588</ArticleId><ArticleId IdType="pubmed">33571321</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou X., Chen K., Zou J., Han P., Hao J., Han Z. (2020). Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front. Med. 14, 1. 10.1007/s11684-020-0754-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11684-020-0754-0</ArticleId><ArticleId IdType="pmc">PMC7088738</ArticleId><ArticleId IdType="pubmed">32170560</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuckerman S., Barlavie Y., Niv Y., Arad D., Lev S. (2022). Accessing unproven interventions in the COVID-19 pandemic: Discussion on the ethics of &#x2018;compassionate therapies&#x2019; in times of catastrophic pandemics. J. Med. Ethics 48, 1000&#x2013;1005. 10.1136/MEDETHICS-2020-106783</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/MEDETHICS-2020-106783</ArticleId><ArticleId IdType="pubmed">34645620</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>